Science
Nieves Martinez Lago: Fruquintinib Shows Real-World Activity in Patients With Colorectal Cancer
Nieves Martinez Lago/LinkedIn

Nieves Martinez Lago: Fruquintinib Shows Real-World Activity in Patients With Colorectal Cancer

Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared on X:

” Fruquintinib | RWE mCRC | Japan

  • 171 pts | 23 centers
  • PFS 2.5 mo | OS 5.8 mo
  • DCR 38.1%
  • G≥3 AEs 49.1%
  • Proteinuria = main cause of treatment modification

Careful toxicity management may help maintain treatment continuity.”

Title: Real-world efficacy, safety, and treatment continuity of fruquintinib in Japanese patients with colorectal cancer: a multicentre retrospective study

Authors: T. Ito, K. Shiraishi, Y. Ishizuka, N. Ishibashi, S. Kameishi, Y. Kito, A. Sugaya, N. Takahashi, H. Kodama, S. Ueno, H. Sagara, S. Kurata, F. Hanamura, K. Hino, Y. Kono, T. Yoshihiro, T. Sakakida, T. Koyama, M. Wakabayashi, N. Suzuki, T. Takayama, N. Tsuruta, K. Baba, A. Nakata, K. Hirata

Read the full article.

A. Nakata A. Sugaya cancer colorectal cancer F. Hanamura H. Kodama H. Sagara K. Baba K. Hino K. Hirata K. Shiraishi M. Wakabayashi N. Ishibashi N. Suzuki N. Takahashi N. Tsuruta Nieves Martinez Lago OncoDaily Oncology S. Kameishi S. Kurata S. Ueno T. Ito T. Koyama T. Sakakida T. Takayama T. Yoshihiro Y. Ishizuka Y. Kito Y. Kono